Business Context and Reporting Period
Company: Immix Biopharma, Inc. (IMMX)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Immix is a clinical-stage biopharmaceutical company focused on developing chimeric antigen receptor (CAR-T) cell therapies, primarily for light chain (AL) Amyloidosis. Its lead candidate, NXC-201, targets B-cell maturation antigen (BCMA) and has received FDA Breakthrough Therapy, Regenerative Medicine Advanced Therapy (RMAT), and Orphan Drug Designations. The company operates as a single segment and has incurred significant losses since inception.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(29.4) million | $(21.7) million |
| Accumulated Deficit | $(104.5) million | $(75.0) million |
| Operating Expenses | $29.96 million | $22.67 million |
| Research & Development (R&D) | $16.26 million | $11.29 million |
| General & Administrative (G&A) | $13.70 million | $11.38 million |
| Cash, Cash Equivalents & Short-Term Investments | $100.4 million | $17.7 million |
| Net Cash Used in Operating Activities | $(23.9) million | $(14.6) million |
| Net Cash Provided by Financing Activities | $107.4 million | $15.9 million |
Note: The company has no product revenue. R&D expenses are partially offset by grant reimbursements.
Material Changes vs. Prior Period
- Capital Raising: In 2025, the company significantly strengthened its balance sheet through multiple financing events, raising approximately $107.4 million in net proceeds. This included a December 2025 underwritten public offering of ~$93.7 million (net), a September 2025 private placement of ~$9.3 million (net), and At-The-Market (ATM) sales of ~$4.4 million (net). In contrast, 2024 financing totaled ~$15.9 million.
- Expense Growth: Total operating expenses increased by approximately 32% year-over-year, driven by a 44% increase in R&D expenses due to the expansion of the NEXICART-2 clinical trial and a 20% increase in G&A expenses due to higher compensation and professional fees.
- Liquidity: Cash and short-term investments grew from $17.7 million at the end of 2024 to $100.4 million at the end of 2025, extending the company's operational runway.
- Grant Funding: The company received $2.8 million in reimbursements from the California Institute for Regenerative Medicine (CIRM) in 2025, compared to $1.9 million in 2024.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Clinical Progress: In December 2025, the company announced positive interim Phase 2 data for NXC-201, showing a 75% complete response rate in relapsed/refractory AL Amyloidosis patients. In January 2026, the FDA granted Breakthrough Therapy designation.
- Runway: Management believes current cash resources ($100.4 million) plus expected CIRM grant disbursements will fund operations for at least 12 months from the filing date. However, additional capital will be required to complete development and commercialization.
- Strategy: The company plans to continue the NEXICART-2 trial (targeting 40 patients) and pursue a Biologics License Application (BLA) submission upon final readout.
Risks and Contingencies
- Capital Needs: The company has no approved products and expects to incur substantial losses for the foreseeable future. Failure to raise additional capital could force delays or termination of development programs.
- Grant Uncertainty: Approximately $1.8 million of the $8 million CIRM grant remains to be received, contingent on meeting specific milestones. Failure to meet these could impact funding.
- Regulatory and Clinical Risk: Clinical trials are expensive and uncertain. Results may not satisfy FDA requirements, or the therapy may exhibit safety issues (e.g., cytokine release syndrome), though no neurotoxicity has been observed to date.
- Intellectual Property: The company relies on licensed technology from Hadasit and BIRAD, requiring ongoing royalty payments and milestone fees upon commercial success.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $100.4 million cash balance against the projected burn rate for the NEXICART-2 trial completion and potential BLA submission.
- CIRM Grant Milestones: Confirm the specific patient enrollment milestones required to secure the remaining $1.8 million of the CIRM grant.
- Clinical Trial Data: Review the full interim data presentation from the ASH 2025 meeting regarding the 75% complete response rate and safety profile (specifically cytokine release syndrome grades) of NXC-201.
- Licensing Obligations: Assess the financial impact of the Hadasit/BIRAD license agreement, including the $13 million in quarterly payments due through 2026 and potential future royalties.
- Dilution Risk: Evaluate the impact of the recent equity issuances (December 2025 offering and September 2025 private placement) on existing shareholder ownership percentages.